GGI
BMRN icon

Godsey & Gibb Inc’s BioMarin Pharmaceuticals BMRN Stock Holding History

Godsey & Gibb Inc’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-250
Closed -$22.1K – 360
2023
Q3 		$22.1K Hold
250
– – ﹤0.01% 201
2023
Q2 		$21.7K Hold
250
– – ﹤0.01% 216
2023
Q1 		$24.3K Buy
+250
New +$25.9K ﹤0.01% 199

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Godsey & Gibb Inc's BMRN Position: Q4 2023 in Review

Godsey & Gibb Inc sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2023, closing a stake of 250 shares — an estimated $22.1K sold.

Godsey & Gibb Inc first reported a position in BMRN in Q1 2023 and held it in 3 quarters. The position peaked at $24.3K in Q1 2023. 547 funds tracked by Wall St. Rank hold BMRN as of Q4 2023.

  • Godsey & Gibb Inc reported no remaining BioMarin Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Godsey & Gibb Inc sold 250 BioMarin Pharmaceuticals shares in Q4 2023, an estimated $22.1K.
  • Godsey & Gibb Inc first reported a position in BioMarin Pharmaceuticals in Q1 2023 and held it in 3 quarters.
  • Godsey & Gibb Inc's BioMarin Pharmaceuticals position peaked at $24.3K in Q1 2023.
  • 547 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2023.

Based on Godsey & Gibb Inc's 13F filing for Q4 2023, filed 16 Jan 2024.